Medicines Co. (MDCO): Top Pick for 2018 - Chardan

Chardan Capital Markets analyst, Gbola Amusa, reiterated his Buy rating on shares of The Medicines Company (NASDAQ: MDCO) and highlighted it as is top pick for 2018. The analyst sees PCSK9 inhibitor macro considerations (including upcoming ODYSSEY Outcomes results), inclisiran's unprecedented clinical profile in hypercholesterolemia, and newly-disclosed inclisiran pivotal trial momentum as deciding factors in the selection.

The analyst also took a victory lap noting "Our 6 Chardan Top Picks for 2017 generated +65.1% average relative performance versus the biotech index and +80.9% average absolute performance".

No change to the price target of $85.

For an analyst ratings summary and ratings history on The Medicines Company click here. For more ratings news on The Medicines Company click here.

Shares of The Medicines Company closed at $30.47 yesterday.

You May Also Be Interested In

• Freedom Broker Upgrades John B. Sanfilippo & Son, Inc. (JBSS) to Buy
• Rubrik Inc (RBRK) PT Raised to $120 at Oppenheimer; Sees Another 'Beat and Raise'
• Nutanix (NTNX) PT Raised to $80 at Oppenheimer Into EPS